


EXHIBIT A


45. A composition comprising a polycarbonate in an admixture with a compound of the formula



46. The composition as claimed in claim 45, wherein said compound is in an amount from about 0.005 to about 5 weight percent of the polycarbonate.

47. The composition as claimed in claim 46, wherein said compound is in an amount from about 0.01 to 2 weight percent of the polycarbonate.

48. A method for inhibiting yellowing and oxidation in a polycarbonate comprising mixing said polycarbonate with 0.005 to about 5 weight percent of a compound of the formula




49. The method as claimed in claim 48 wherein said compound is in an amount from about 0.01 to 2 weight %.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in cursive script, reading "Thomas J. McGinnis".

Thomas J. McGinnis, R.Ph.
Deputy Associate Commissioner
for Health Affairs

cc: Teresa Stanek Rea
Burns, Doane, Swecker & Mathis, LLP
P.O. Box 1404
Alexandria, VA 22313-1404